Company intelligence / Profile preview
Conformation-X Therapeutics
Canton, Massachusetts, United Statesconformationx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Conformation-X Therapeutics has demonstrated successful ex vivo and in vivo proof-of-concept for its lead programs targeting HHLA2 and IL18BP. These assets represent novel immune checkpoint inhibitors designed to activate both the innate and adaptive arms of the immune system. The company’s approach aims to address cancer mechanisms that evade current immunotherapies, particularly focusing on tumors resistant to existing checkpoint blockade therapies. The company recently raised over $13.5M to advance these preclinical assets toward translational studies.
- Therapeutic areas
- Oncology
- Modalities
- Biologics (immune checkpoint inhibitors)Small molecules (orally available drugs)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Conformation-X Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Conformation-X Therapeutics.